Lixte Biotechnology Holdings, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Lixte Biotechnology Holdings, Inc. has filed its 2023 10-K report detailing its financial performance and operational aspects.</b>

AI Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed a Annual Report (10-K) with the SEC on March 19, 2024. Lixte Biotechnology Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its fiscal year ends on December 31. The filing covers the period from January 1, 2023, to December 31, 2023. Key financial statement information, including common stock and preferred stock details, is provided for fiscal years 2021, 2022, and 2023. The report addresses supplier concentration risks related to legal firms and other vendors, as well as directors and corporate officers.

Why It Matters

For investors and stakeholders tracking LIXTE BIOTECHNOLOGY HOLDINGS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Lixte Biotechnology's financial health, operational risks, and strategic positioning for the fiscal year 2023, which is crucial for investors to assess the company's current status and future prospects. The detailed financial data and risk factor disclosures within the report are essential for stakeholders to understand the company's financial stability, potential challenges, and compliance with regulatory requirements.

Risk Assessment

Risk Level: medium — LIXTE BIOTECHNOLOGY HOLDINGS, INC. shows moderate risk based on this filing. The company's financial disclosures are limited in this extract, making a full assessment of its financial health difficult, but the mention of supplier concentration risks suggests potential operational vulnerabilities.

Analyst Insight

Investors should review the full 10-K filing to understand Lixte Biotechnology's financial performance, clinical trial progress, and any specific risks or opportunities identified for the upcoming fiscal year.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-19 — Filing Date (Date of submission)
• 2023-01-01 — Reporting Period Start Date (Fiscal year)
• 2022-12-31 — Prior Year End (Comparative financial data)
• 2021-12-31 — Prior Year End (Comparative financial data)

Key Players & Entities

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer name
• LIXT (company) — Ticker symbol
• 2023-12-31 (date) — Fiscal year end
• 2024-03-19 (date) — Filing date
• DE (jurisdiction) — State of incorporation
• 2834 (industry_code) — Standard Industrial Classification
• SRKP 7 INC (company) — Former company name
• 2005-08-03 (date) — Date of name change

FAQ

Risk Factors

• Supplier Concentration Risk [medium — operational]: The company faces supplier concentration risk, particularly with legal firms and other vendors, as well as directors and corporate officers, for general and administrative expenses.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-03-19: Filing Date — Date the 10-K was officially submitted to the SEC.

Key Financial Figures

• $0.0001 — Section 12(b) of the Act: Common Stock, $0.0001 par value. Title of each class Trad

Filing Documents

• form10-k.htm (10-K) — 2352KB
• ex10-16.htm (EX-10.16) — 57KB
• ex23-1.htm (EX-23.1) — 3KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• form10-k_001.jpg (GRAPHIC) — 60KB
• form10-k_002.jpg (GRAPHIC) — 53KB
• form10-k_003.jpg (GRAPHIC) — 92KB
• form10-k_004.jpg (GRAPHIC) — 74KB
• 0001493152-24-010427.txt (&nbsp;) — 8793KB
• lixt-20231231.xsd (EX-101.SCH) — 47KB
• lixt-20231231_cal.xml (EX-101.CAL) — 40KB
• lixt-20231231_def.xml (EX-101.DEF) — 249KB
• lixt-20231231_lab.xml (EX-101.LAB) — 426KB
• lixt-20231231_pre.xml (EX-101.PRE) — 338KB
• form10-k_htm.xml (XML) — 1126KB

BUSINESS

BUSINESS 4 ITEM 1A.

RISK FACTORS

RISK FACTORS 15 ITEM 1B. UNRESOLVED STAFF COMMENTS 52 ITEM 1C CYBERSECURITY 53 ITEM 2.

PROPERTIES

PROPERTIES 53 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 53 ITEM 4. MINE SAFETY DISCLOSURES 53 PART II 54 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 54 ITEM 6. RESERVED 55 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 56 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 73 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 73 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 73 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 73 ITEM 9B. OTHER INFORMATION 75 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 75 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 76 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 82 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 92 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE 93 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 93 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 94 ITEM 16. FORM 10-K SUMMARY 94 INDEX TO EXHIBITS 95

SIGNATURES

SIGNATURES 97 CONSOLIDATED FINANCIAL STATEMENTS F-1 -2- Introductory Comment Throughout this Annual Report on Form 10-K, the terms "we," "us," "our," "our company," "Lixte," the "Company" and the "Registrant" refer to Lixte Biotechnology Holdings, Inc., a Delaware corporation, and Lixte Biotechnology, Inc., a Delaware corporation, our wholly-owned subsidiary. FORWARD-LOOKING This Annual Report on Form 10-K (the "Report") contains certain forward-looking statements. For example, statements regarding our financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, competition from other similar businesses, and market and general policies, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the consolidated financial statements and notes

View Full Filing

View this 10-K filing on SEC EDGAR